Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431124 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571418 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL12897943 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL18269413 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL3221050 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL245092 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13625375 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL245091 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL30571404 | 1.00 | HMGCR (0.74) | HMGCR | |
| SCHEMBL13764732 | 1.00 | HMGCR (0.74) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2019-09-19 | — | — | US | disclosed |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | EMPIRIKO CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140105822-A1 | NANOSPHERES COMPRISING TOCOPHEROL, AN AMPHIPHILIC SPACER AND A THERAPEUTIC OR IMAGING AGENT | CEDARS-SINAI MEDICAL CENTER (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105822-A1 | NANOSPHERES COMPRISING TOCOPHEROL, AN AMPHIPHILIC SPACER AND A THERAPEUTIC OR IMAGING AGENT | CEDARS-SINAI MEDICAL CENTER (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2013016696-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | CEDARS-SINAI MEDICAL CENTER (US) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | HMGCR 213/4885 |
| US-20140105822-A1 | NANOSPHERES COMPRISING TOCOPHEROL, AN AMPHIPHILIC SPACER AND A THERAPEUTIC OR IMAGING AGENT | TTPA, NFE2, GSTK1 | HMGCR 4/4885 |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | HMGCR 213/4885 |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | CYP3A43, CYP3A4, CYP2D6 | HMGCR 213/4885 |
| US-20140140931-A1 | ANTIOXIDANT, NEUROPROTECTIVE AND ANTINEOPLASTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT ON AN AMPHIPHILIC SPACER OR AN AMPHIPHILIC POLYMER | NLN, CASP12, GPX4 | HMGCR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.